RxDoctor Payments Data

Steven Paris

Primary Care · Austin, TXNPI 1629622071

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,942 of the $10,484 with a category attached, or 75.8%. 27 manufacturers reported payments, led by Merck at 25.9% of the total. 2025 is the largest year on record at $5,938, more than ten times the $426 reported in 2021. Among primary care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,484in general payments, 2019–2025

Across 338 payments — averaging $31.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$3K
  • Gilead$3K
  • Viiv Healthcare Company$3K
  • Theratechnologies Inc.$629
  • Novo Nordisk$440
  • AstraZeneca$211
  • plus $1K from 21 others

What the payments were for

  • Consulting fees$5005%
  • Travel & lodging$2,04119%
  • Food & beverage$7,94276%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,484 in reported general payments places this provider in the 95th percentile of 563 primary care providers in Texas.

See all primary care providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide25$29,128
OzempicSemaglutide19$20,703
Albuterol Sulfate HfaAlbuterol Sulfate12$281
Estradiol12$202
Amlodipine Besylate15$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$199$29,12825 claims
Novo NordiskOzempic$440$20,70319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 563 primary care providers in Texas.

Other primary care in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →